Papillomavirus vaccine types 16 and 18: new drug. Cervical cancer: just another vaccine.
The papillomavirus 16, 18 vaccine, like the papillomavirus 6, 11, 16, 18 vaccine, reduces the risk of high-grade cervical dysplasia due to all viral genotypes by about 40% in young women who are not yet infected at the time of vaccination. The vaccine does not seem to provoke any serious adverse effects, but there is no proof that it reduces the risk of cancer.
D002986:Clinical Trials as Topic; D003218:Condylomata Acuminata / Q000517:prevention & control / Q000821:virology; D017277:Drug Approval; D005060:Europe; D005260:Female; D052162:Human papillomavirus 16 / Q000276:immunology / Q000472:pathogenicity; D052161:Human papillomavirus 18 / Q000276:immunology / Q000472:pathogenicity; D006801:Humans; D030361:Papillomavirus Infections / Q000276:immunology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002578:Uterine Cervical Dysplasia / Q000517:prevention & control / Q000821:virology; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control* / Q000821:virology
D053918:Papillomavirus Vaccines